TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05308368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography
Description: We will collect electromyography (EMG) signals of both the flexor and extensor muscles of the wrist during the grasping motion for both groups

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography
Description: We will collect electromyography (EMG) signals of both the flexor and extensor muscles of the wrist during the grasping motion for both groups

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inertial Measurement Units (IMU)
Description: We will use data from the ultrasound images and EMG to develop a tremor model. The model will be validated in comparison to joint angle measurements from an Inertial Measurement Unit (IMU) collected during the grasping motion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inertial Measurement Units (IMU)
Description: We will use data from the ultrasound images and EMG to develop a tremor model. The model will be validated in comparison to joint angle measurements from an Inertial Measurement Unit (IMU) collected during the grasping motion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Description: We will use the develop closed-loop control methods for tremor suppression using information from the ultrasound-image based tremor models. FES will be used to provide stimulation that will help with tremor suppression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Description: We will use the develop closed-loop control methods for tremor suppression using information from the ultrasound-image based tremor models. FES will be used to provide stimulation that will help with tremor suppression
Study: NCT01273480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1
Description: Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2
Description: Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
Study: NCT04344158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib Tosylate Tablets
Description: Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
Study: NCT00952224

Intervention type: OTHER
Intervention: magnetic resonance imaging
Description: magnetic resonance imaging is used for prognosis assessment
Study: NCT04066413

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant formula
Description: Standard infant formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula supplemented with HMO
Description: Infant formula supplemented with HMO
Study: NCT00458289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum carbonate (chewed vs. crushed)
Description: single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum carbonate (chewed vs. crushed)
Description: single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
Study: NCT01287715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: etanercept
Description: Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
Study: NCT03876028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral (tablets or capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral (tablets or capsules)
Study: NCT00987025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Use of telehealth blood pressure station every week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Control
Study: NCT02824887

Intervention type: OTHER
Intervention: Electro-acupuncture
Description: Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints

Intervention type: OTHER
Intervention: Conventional treatment of Western Medicine
Description: Routine non operative treatment of Western Medicine
Study: NCT03996616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Head UP Position
Description: CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).~Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a \<10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impedance Threshold Device
Description: An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Automated CPR
Description: Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).
Study: NCT00549341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin
Description: 100U vials, doses ranged from 50U-200U, single injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Single injection.
Study: NCT02901821

Intervention type: GENETIC
Intervention: salivary RNA collection
Description: collection of saliva for microRNA (small noncoding RNA) processing

Intervention type: GENETIC
Intervention: salivary RNA collection
Description: collection of saliva for microRNA (small noncoding RNA) processing
Study: NCT06613815

Intervention type: OTHER
Intervention: radiofrequency of the geniculate nerves
Description: radiofrequency of the geniculate nerveswith a scopy-guided technique versus the ultrasound-guided technique

Intervention type: OTHER
Intervention: radiofrequency of the geniculate nerves
Description: radiofrequency of the geniculate nerveswith a scopy-guided technique versus the ultrasound-guided technique
Study: NCT00076245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: Light therapy will involve exposure to bright light twice a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: Light therapy will involve exposure to bright light twice a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
Study: NCT05188924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-306
Description: Active ingredients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02400515

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: This is a quasi-experimental study and the same group was evaluated before and after the exercise.
Study: NCT04523246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)
Description: The Shingrix vaccine is a subunit vaccine that contains the recombinant varicella zoster virus (VZV) glycoprotein E (gE), adjuvanted with the proprietary Adjuvant System (AS01B). The AS01B Adjuvant system consists of two immune-stimulants, the saponin, Quillaja saponaria Molina, fraction 21 (QS21), and the toll-like receptor 4 (TLR4) agonist, MPL (3-O-desacyl-40-MPL) that enhance the release of interferon gamma (IFNϒ), which in turn stimulates activation and recruitment of blood monocyte-derived and resident lymph node dendritic cells to take up and present gE to cluster of differentiation 4 (CD4+) T cells.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sterile normal saline, inactive control.
Study: NCT01325506

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire, telephone interviews, and clinical follow-up
Study: NCT01765270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: one 5-mg saxagliptin tablet daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg placebo tablet daily
Study: NCT00459823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7107
Description: E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
Study: NCT03244982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein Na 10% Inj 500mg
Description: Full-dose intravenous Fluorescein Na prior to fluorescein angiography.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Na 10% Inj 500mg
Description: Full-dose intravenous Fluorescein Na prior to fluorescein angiography.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein Na 10% Inj 250mg
Description: Half-dose intravenous Fluorescein Na prior to fluorescein angiography.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Na 10% Inj 250mg
Description: Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
Study: NCT04366596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty with paclitaxel eluting balloon
Description: The patients will be treated with renal artery angioplasty using paclitaxel eluting balloon

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Angioplasty with plain old balloon
Description: Angioplasty with plain old balloon
Study: NCT03821792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT03583528

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-DOTATOC PET/CT
Description: Blood pressure, heart rate, and oxygen saturation levels will be recorded prior to the injection and at 5 - 15 minutes after injection.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. After this uptake phase, the blood pressure, heart rate, and oxygen saturation levels will be recorded again. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT For 18F-FDG as fasting period of 6 hours is required before the scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.
Study: NCT01609231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m\^2 followed by weekly infusions of 250 mg/m\^2. Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
Study: NCT02366988

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Biliary Stenting
Description: Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment Bilio-enteric anastomosis
Description: Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
Study: NCT00471146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: oral administration, starting dose 5 mg twice daily \[BID\] every day until unacceptable toxicity or tumor progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03422042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short duration of antibiotic
Description: Patient will received intravenous antibiotic until the body temperature is less than 37.8 c fir 72, then antibiotic is discontinued.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment of antibiotic
Description: Patient will received intravenous antibiotic for 7 days, followed by oral antibiotic for 7 days, regardless of the body temperature.
Study: NCT04288180

Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.
Study: NCT01044719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Tobramycin 7mg/kg/day OD IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Tobramycin 7mg/kg/day OD IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Tobramycin 7mg/kg/day OD IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 2g TDS IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 2g TDS IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 2g TDS IV
Study: NCT03272321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Syntocinon nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study: NCT01014312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Care Management (DCM)
Description: Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care
Description: Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
Study: NCT00753766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial Intervention
Study: NCT01518023

Intervention type: OTHER
Intervention: Interview, questionnaire, updated biochemical tests
Description: Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.

Intervention type: OTHER
Intervention: Interview, questionnaire, updated biochemical tests
Description: Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.

Intervention type: OTHER
Intervention: Interview, questionnaire, updated biochemical tests
Description: Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
Study: NCT01067066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
Study: NCT06616506

Intervention type: DEVICE
Intervention: newly-invented AI model
Description: Apply newly-invented AI models to assist in determining surgical plans and outcome prediction.
Study: NCT01067066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar (Temozolomide)
Description: Starting dose cycle 1, 85 mg/m\^2 by mouth (PO) daily, Day 1 to 5.
Study: NCT02478372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Epidural (PCEA)
Description: Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Infiltration Analgesia (LIA)
Description: Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
Study: NCT02651350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
Study: NCT02643290

Intervention type: DEVICE
Group type: OTHER
Intervention: Peak Scoliosis Bracing System
Description: Brace is fit to adult scoliosis patients for 2-4 hours a day and tracked for six months.
Study: NCT06616506

Intervention type: DEVICE
Intervention: newly-invented AI model
Description: Apply newly-invented AI models to assist in determining surgical plans and outcome prediction.

Intervention type: DEVICE
Intervention: newly-invented AI model
Description: Apply newly-invented AI models to assist in determining surgical plans and outcome prediction.

Intervention type: DEVICE
Intervention: newly-invented AI model
Description: Apply newly-invented AI models to assist in determining surgical plans and outcome prediction.
Study: NCT02620007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks